IO Biotech Inc
IOBT
Company Profile
Business description
IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer vaccines based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression.
Contact
Ole Maaloes Vej 3
Copenhagen NDK-2200
DNKT: +45 70702980
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
78
Stocks News & Analysis
stocks
Markets brief: How will AI affect economic moats? Morningstar’s take on the new paradigm
A broad assessment of AI’s threats and opportunities leads to moat ratings changes for more than three dozen companies.
stocks
Baidu: Moat downgraded to none from wide; AI segment growth to offset search decline in long \run
We’ve also lowered our fair value estimate of Baidu stock.
stocks
What AI means for US software companies’ moats
We’re no longer certain that software firms will outperform over the next decade, but positive outcomes remain possible for names like Salesforce.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,823.60 | 16.90 | -0.19% |
| CAC 40 | 7,915.36 | 78.13 | -0.98% |
| DAX 40 | 23,409.37 | 181.66 | -0.77% |
| Dow JONES (US) | 47,740.80 | 239.25 | 0.50% |
| FTSE 100 | 10,249.52 | 35.23 | -0.34% |
| HKSE | 25,408.46 | 348.83 | -1.35% |
| NASDAQ | 22,695.95 | 308.27 | 1.38% |
| Nikkei 225 | 52,728.72 | 2,892.12 | -5.20% |
| NZX 50 Index | 13,236.20 | 137.37 | 1.05% |
| S&P 500 | 6,795.99 | 55.97 | 0.83% |
| S&P/ASX 200 | 8,599.00 | 3.30 | -0.04% |
| SSE Composite Index | 4,096.60 | 27.59 | -0.67% |